IN2014MN01882A - - Google Patents

Info

Publication number
IN2014MN01882A
IN2014MN01882A IN1882MUN2014A IN2014MN01882A IN 2014MN01882 A IN2014MN01882 A IN 2014MN01882A IN 1882MUN2014 A IN1882MUN2014 A IN 1882MUN2014A IN 2014MN01882 A IN2014MN01882 A IN 2014MN01882A
Authority
IN
India
Prior art keywords
compounds
pharmaceutically acceptable
drug resistant
present
resistant organisms
Prior art date
Application number
Other languages
English (en)
Inventor
Helen Mcguire
Shanta Bist
Neil Bifulco
Liang Zhao
Ye Wu
Hoan Huynh
Hui Xiong
Prevoir Janelle Comita
Daemian Dussault
Bolin Geng
Brendan Chen
Reville Thomas Durand
Satenig Guler
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IN2014MN01882A publication Critical patent/IN2014MN01882A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN1882MUN2014 2012-04-02 2013-04-02 IN2014MN01882A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261618993P 2012-04-02 2012-04-02
PCT/GB2013/050869 WO2013150296A1 (fr) 2012-04-02 2013-04-02 Composés hétérobicycliques comme inhibiteurs de la bêta-lactamase

Publications (1)

Publication Number Publication Date
IN2014MN01882A true IN2014MN01882A (fr) 2015-07-10

Family

ID=48083562

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1882MUN2014 IN2014MN01882A (fr) 2012-04-02 2013-04-02

Country Status (41)

Country Link
US (2) US9309245B2 (fr)
EP (1) EP2834239B1 (fr)
JP (1) JP6122484B2 (fr)
KR (1) KR102042867B1 (fr)
CN (1) CN104364254B (fr)
AP (1) AP2014007980A0 (fr)
AR (1) AR090539A1 (fr)
AU (1) AU2013245399B2 (fr)
BR (1) BR112014024279B1 (fr)
CA (1) CA2866467C (fr)
CL (1) CL2014002589A1 (fr)
CO (1) CO7071137A2 (fr)
CR (1) CR20140428A (fr)
CY (1) CY1120269T1 (fr)
DK (1) DK2834239T3 (fr)
DO (1) DOP2014000212A (fr)
ES (1) ES2663416T3 (fr)
HR (1) HRP20180450T1 (fr)
HU (1) HUE036722T2 (fr)
IL (1) IL234660A (fr)
IN (1) IN2014MN01882A (fr)
LT (1) LT2834239T (fr)
MA (1) MA37383A1 (fr)
ME (1) ME03031B (fr)
MX (1) MX354627B (fr)
MY (1) MY176969A (fr)
NO (1) NO2935238T3 (fr)
NZ (1) NZ630259A (fr)
PE (1) PE20142403A1 (fr)
PH (1) PH12014502224B1 (fr)
PL (1) PL2834239T3 (fr)
PT (1) PT2834239T (fr)
RS (1) RS56966B1 (fr)
RU (1) RU2645678C2 (fr)
SG (1) SG11201405965RA (fr)
SI (1) SI2834239T1 (fr)
SM (1) SMT201800142T1 (fr)
TN (1) TN2014000417A1 (fr)
TW (1) TWI597281B (fr)
UY (1) UY34723A (fr)
WO (1) WO2013150296A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
LT3221313T (lt) * 2014-11-17 2019-03-25 Entasis Therapeutics Limited Derinių terapija, skirta atsparių bakterinių infekcijų gydymui
CN107438610A (zh) 2015-03-31 2017-12-05 拜欧蒂姆公司 杂环化合物及它们在预防或治疗细菌感染中的应用
EP3075733A1 (fr) * 2015-03-31 2016-10-05 Mutabilis Nouveaux composés hétérocycliques et leur utilisation dans la prévention ou le traitement d'infections bactériennes
EP3277686B1 (fr) 2015-03-31 2020-07-22 Mutabilis Nouveaux composés hétérocycliques et leur utilisation dans la prévention ou le traitement d'infections bactériennes
KR20170132316A (ko) * 2015-04-03 2017-12-01 무타빌리스 헤테로고리 화합물 및 박테리아 감염의 예방 또는 치료에서 그들의 용도
EP3075381A1 (fr) * 2015-04-03 2016-10-05 Mutabilis Nouveaux composés hétérocycliques et leur utilisation dans la prévention ou le traitement d'infections bactériennes
EP3091018A1 (fr) * 2015-05-07 2016-11-09 Mutabilis Nouveaux composés hétérocycliques et leur utilisation dans la prévention ou le traitement d'infections bactériennes
CA2983674A1 (fr) * 2015-05-07 2016-11-10 Mutabilis Composes heterocycliques et leur utilisation dans la prevention ou le traitement d'infections bacteriennes
TW201725205A (zh) 2015-10-02 2017-07-16 樂高化學生物科學股份有限公司 用於抑制β-內醯胺酶之組合物及方法
EP3184529A1 (fr) 2015-12-23 2017-06-28 Mutabilis Nouveaux composés hétérocycliques et leur utilisation dans la prévention ou le traitement d'infections bactériennes
WO2017203266A1 (fr) 2016-05-25 2017-11-30 Entasis Therapeutics Limited Polythérapie pour le traitement d'infections bactériennes résistantes
AU2017325863B2 (en) * 2016-09-16 2021-08-19 Entasis Therapeutics Limited Beta-lactamase inhibitor compounds
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
EP3300736B1 (fr) 2016-09-30 2021-05-05 Mutabilis Composition comprenant un composé antibiotique et un composé hétérocyclique et leur utilisation pour prévenir ou traiter des infections bactériennes
EP3301094A1 (fr) * 2016-09-30 2018-04-04 Mutabilis Nouveaux composés hétérocycliques et leur utilisation dans la prévention ou le traitement d'infections bactériennes
EA202190617A3 (ru) * 2017-02-08 2021-10-29 Энтасис Терапеутикс Лимитед Соединения-ингибиторы бета-лактамаз
PL3630111T3 (pl) 2017-05-08 2022-05-23 Entasis Therapeutics, Inc. Związki i sposoby leczenia zakażeń bakteryjnych
US10085999B1 (en) * 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
EP3795149A4 (fr) 2018-05-14 2022-01-05 National University Corporation Tokai National Higher Education and Research System Inhibiteur de beta-lactamase
ES2960952T3 (es) * 2018-08-09 2024-03-07 Antabio Sas Diazabiciclooctanonas como inhibidores de serina beta-lactamasas
EP3608318A1 (fr) * 2018-08-09 2020-02-12 Antabio SAS Derives de diaazabicyclooctanone comme antibiotiques
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
RU2739761C2 (ru) * 2018-09-27 2020-12-28 Федеральное государственное бюджетное научное учреждение Уфимский федеральный исследовательский центр Российской академии наук Способ получения n-алкил-n-{ [3-алкил-3,8-диазабицикло[3.2.1]окта-1(7),5-диен-8-ил]метил} аминов и их применение в качестве средств с антимикробной активностью
CN111196808B (zh) * 2018-11-16 2022-10-18 南京圣和药业股份有限公司 二氮杂双环类化合物及其应用
CN110615790A (zh) * 2019-10-24 2019-12-27 北京融英医药科技有限公司 一种利格列汀制备工艺的改进方法
US20220194791A1 (en) * 2020-12-22 2022-06-23 Tokyo Ohka Kogyo Co., Ltd. Method for producing aqueous solution of purified orthoperiodic acid, method for producing semiconductor device, and aqueous solution of orthoperiodic acid
EP4281042A1 (fr) * 2021-01-20 2023-11-29 Entasis Therapeutics Limited Compositions d'antibiotiques à dose fixe
CN113979981B (zh) * 2021-10-22 2023-04-07 天津医科大学 一种巯基响应型脱碱基位点捕获试剂及应用
WO2023206580A1 (fr) 2022-04-29 2023-11-02 Entasis Therapeutics Limited Formes cristallines de durlobactam
CN118271319B (zh) * 2022-12-30 2025-02-28 成都四面体药物研究有限公司 一种β-内酰胺酶抑制剂含脲双环化合物、其制备方法及其用途
WO2024227071A1 (fr) 2023-04-26 2024-10-31 Entasis Therapeutics Limited Synthèse de durlobactam
CN116693531A (zh) * 2023-06-09 2023-09-05 河南师范大学 一种桥联多环内酰胺类化合物的合成方法
AU2024322286A1 (en) 2023-08-08 2026-03-26 Chengdu Tetrahedral Drug Research Co., Ltd UREA-CONTAINING TRICYCLIC β-LACTAMASE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF
WO2025106662A1 (fr) 2023-11-15 2025-05-22 Entasis Therapeutics, Inc. Préparation d'intermédiaires d'acide boronique utiles dans la préparation de composés pour le traitement d'infections bactériennes
WO2025239896A1 (fr) 2024-05-16 2025-11-20 Entasis Therapeutics, Inc. Traitement de pneumonie bactérienne nosocomiale et pneumonie bactérienne acquise sous ventilation mécanique provoquée par des isolats sensibles de complexe acinetobacter baumannii-calcoaceticus

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2127946T3 (es) * 1993-12-29 1999-05-01 Pfizer Antagonistas de neurocinina diazabiciclica.
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
SI2666774T1 (sl) 2008-01-18 2015-04-30 Merck Sharp & Dohme Corp. Inhibitorji beta- laktamaze
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP3260551A1 (fr) * 2008-06-19 2017-12-27 Astra Zeneca Holding France Utilisation de (1r, 2s, 5r) 1,6-diazabicyclo [3.2.1] octane-2-carboxamide, 7-oxo-6-(sulfooxy) -, sel monosodique en tant que réactif de diagnostic pour la détection de sérines bêta-lactamases
FR2936798B1 (fr) * 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2937034B1 (fr) 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
BR112013028813B1 (pt) 2011-08-27 2020-10-20 Wockhardt Limited derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e composições farmacêuticas que os compreendem
MX340533B (es) 2011-08-30 2016-07-13 Wockhardt Ltd Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
AU2012310136B2 (en) 2011-09-13 2016-07-07 Wockhardt Limited Nitrogen containing compounds and their use
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
SG11201406120SA (en) 2012-03-30 2014-10-30 Cubist Pharm Inc ISOXAZOLE β-LACTAMASE INHIBITORS
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US8933232B2 (en) 2012-03-30 2015-01-13 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
CN105859609B (zh) 2012-05-30 2019-04-09 明治制果药业株式会社 β-内酰胺酶抑制剂及其制备方法
WO2014033560A1 (fr) 2012-08-25 2014-03-06 Wockhardt Limited Dérivés de 1,6-diazabicyclo[3,2,1]octan-7-one et leur utilisation dans le traitement d'infections bactériennes
WO2014141132A1 (fr) 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. Nouveaux composés hétérocycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de β-lactamase

Also Published As

Publication number Publication date
NZ630259A (en) 2016-06-24
BR112014024279B1 (pt) 2021-09-08
US20160175290A1 (en) 2016-06-23
RU2014141579A (ru) 2016-05-27
TW201345907A (zh) 2013-11-16
NO2935238T3 (fr) 2018-05-26
SG11201405965RA (en) 2014-10-30
UY34723A (es) 2015-07-31
AR090539A1 (es) 2014-11-19
RU2645678C2 (ru) 2018-02-27
MA37383A1 (fr) 2016-06-30
CL2014002589A1 (es) 2015-01-30
AU2013245399A1 (en) 2014-10-02
MX354627B (es) 2018-03-14
IL234660A (en) 2017-08-31
CN104364254B (zh) 2017-02-22
WO2013150296A1 (fr) 2013-10-10
HRP20180450T1 (hr) 2018-06-01
HK1207071A1 (en) 2016-01-22
CR20140428A (es) 2015-01-12
PL2834239T3 (pl) 2018-06-29
LT2834239T (lt) 2018-03-26
HUE036722T2 (hu) 2018-07-30
CY1120269T1 (el) 2019-07-10
US9623014B2 (en) 2017-04-18
KR20140140625A (ko) 2014-12-09
RS56966B1 (sr) 2018-05-31
JP2015512440A (ja) 2015-04-27
TN2014000417A1 (en) 2016-03-30
EP2834239A1 (fr) 2015-02-11
TWI597281B (zh) 2017-09-01
CN104364254A (zh) 2015-02-18
ES2663416T3 (es) 2018-04-12
US20150073011A1 (en) 2015-03-12
ME03031B (fr) 2018-10-20
PE20142403A1 (es) 2015-01-23
CA2866467C (fr) 2020-03-24
CA2866467A1 (fr) 2013-10-10
PT2834239T (pt) 2018-03-23
PH12014502224B1 (en) 2017-11-08
DK2834239T3 (en) 2018-03-26
JP6122484B2 (ja) 2017-04-26
SMT201800142T1 (it) 2018-05-02
BR112014024279A8 (pt) 2018-04-03
EP2834239B1 (fr) 2017-12-27
SI2834239T1 (en) 2018-05-31
DOP2014000212A (es) 2014-10-31
CO7071137A2 (es) 2014-09-30
US9309245B2 (en) 2016-04-12
AU2013245399B2 (en) 2016-04-21
AP2014007980A0 (en) 2014-10-31
MX2014011351A (es) 2014-12-05
MY176969A (en) 2020-08-28
BR112014024279A2 (fr) 2017-06-20
PH12014502224A1 (en) 2015-01-12
KR102042867B1 (ko) 2019-11-08

Similar Documents

Publication Publication Date Title
IN2014MN01882A (fr)
TW201713633A (en) Metallo-beta-lactamase inhibitors
PH12019500558A1 (en) Beta-lactamase inhibitor compounds
MX2018010878A (es) Compuestos de aril-monobactam biciclicos y metodos de uso de los mismos para el tratamiento de infecciones bacterianas.
MY179292A (en) Monobactam organic compounds for the treatment of bacterial infections
NZ617104A (en) Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
PH12017500852A1 (en) Combination therapy for treatment of resistant bacterial infections
AU2012302022A8 (en) Antibacterial compounds and methods for use
EA201991523A1 (ru) Комбинированная терапия амидин-замещенными бета-лактамными соединениями и ингибиторами бета-лактамазы при инфекциях, вызванных бактериальными штаммами, резистентными к антибиотикам
MX352760B (es) Metodos para tratar infecciones intrapulmonares.
MX339455B (es) Inhibidores de pirimidina y topoisomerasa iv.
NZ740051A (en) Tetracycline compounds
WO2014022382A3 (fr) Inhibiteurs de protéine kinase antibactérienne
EP2590978A4 (fr) Agents antibactériens de carbapénem avec activité anti-gram négatif
NZ706734A (en) Pharmaceutical compositions useful for the treatment or control of bacterial infections
EP2865668A3 (fr) Inhibiteurs et procédés d'inhibition de pathogènes bactériens et viraux
PH12013501830A1 (en) Peptide deformylase inhibitors
PH12014501215A1 (en) Peptide deformylase inhibitors
GEP20186874B (en) Hydrochloride salts of an antibiotic compound
EA201990738A1 (ru) Соединения-ингибиторы бета-лактамаз
UA83604U (en) Pharmaceutical composition